Onkologie. 2022:16(3):118-122 | DOI: 10.36290/xon.2022.023

News in immunotherapy of dMMR/MSI-H CRC

Marián Liberko1, 2, Renata Soumarová1, 2
1 Onkologická klinika, FNKV a 3. LF UK, Praha
2 3. lékařská fakulta Univerzita Karlova, Praha

Colorectal carcinoma is a heterogenous disease. Advancements in molecular biology of tumors lead to definition of specific subtypes. For many of them targeted therapy known as personalized (precision) treatment is available. dMMR/MSI-H CRC is one of these subtypes, where immunotherapy leads to significant and long lasting response. This review summarizes current options in treatment of dMMR/MSI-H CRC.

Keywords: dMMR/MSI-H CRC, anti PD-1, anti CTLA-4, immunotherapy.

Published: May 16, 2022  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Liberko M, Soumarová R. News in immunotherapy of dMMR/MSI-H CRC. Onkologie. 2022;16(3):118-122. doi: 10.36290/xon.2022.023.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014;64(2):104-117. doi: 10.3322/caac.21220. Epub 2014 Mar 17. PMID: 24639052. Go to original source... Go to PubMed...
    2. Yang Y, Li X, Ma Z, et al. CTLA-4 expression by B-1a B cells is essential for immune tolerance. Nat Commun. 2021;12(1):525. doi: 10.1038/s41467-020-20874-x. PMID: 33483505; PMCID: PMC7822855. Go to original source... Go to PubMed...
    3. Le DT, Durham JN, Smith KN, et al. Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade. Science. 2017;357(6349):409-413. doi: 10.1126/science.aan6733. Epub 2017 Jun 8. PMID: 28596308; PMCID: PMC5576142. Go to original source... Go to PubMed...
    4. Yiemchavee S, Wong-Arce A, Romero-Maldonado A, et al. Expression and immunogenicity assessment of a plant-made immunogen targeting the cytotoxic T-lymphocyte associated antigen-4: a possible approach for cancer immunotherapy. J Biotechnol. 2021;329:29-37. doi: 10.1016/j.jbiotec.2021.01.016. Epub 2021 Jan 21. PMID: 33485860. Go to original source... Go to PubMed...
    5. Jass JR, Do KA, Simms LA, et al. Morphology of sporadic colorectal cancer with DNA replication errors. Gut. 1998;42(5):673-679. doi: 10.1136/gut.42.5.673. PMID: 9659163; PMCID: PMC1727100. Go to original source... Go to PubMed...
    6. Ganesh K, Stadler ZK, Cercek A, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16(6):361-375. doi: 10.1038/s41575-019-0126-x. PMID: 30886395; PMCID: PMC7295073. Go to original source... Go to PubMed...
    7. Galon J, Costes A, Sanchez-Cabo F, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science. 2006;313(5795):1960-1964. doi: 10.1126/science.1129139. PMID: 17008531. Go to original source... Go to PubMed...
    8. Le DT, Uram JN, Wang H, et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med. 2015 Jun 25;372(26):2509-20. doi: 10.1056/NEJMoa1500596. Epub 2015 May 30. PMID: 26028255; PMCID: PMC4481136. Go to original source... Go to PubMed...
    9. Le DT, Kim TW, Van Cutsem E, et al. Phase II Open-Label Study of Pembrolizumab in Treatment-Refractory, Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: KEYNOTE-164. J Clin Oncol. 2020;38(1):11-19. doi: 10.1200/JCO.19.02107. Epub 2019 Nov 14. PMID: 31725351; PMCID: PMC7031958. Go to original source... Go to PubMed...
    10. André T, Shiu KK, Kim TW, et al. KEYNOTE-177 Investigators. Pembrolizumab in Microsatellite-Instability-High Advanced Colorectal Cancer. N Engl J Med. 2020 Dec 3;383(23):2207-2218. doi: 10.1056/NEJMoa2017699. PMID: 33264544. Go to original source... Go to PubMed...
    11. André T, Shiu KK, Kim TW, et al. Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC). Journal of Clinical Oncology. 2021;39(15_suppl):3500-3500. Go to original source...
    12. Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18(9):1182-1191. doi: 10.1016/S1470-2045(17)30422-9. Epub 2017 Jul 19. Erratum in: Lancet Oncol. 2017;18(9):e510. PMID: 28734759; PMCID: PMC6207072. Go to original source... Go to PubMed...
    13. Overman MJ, Bergamo F, McDermott RS, et al. Nivolumab in patients with DNA mismatch repair-deficient/microsatellite instability-high (dMMR/MSI-H) metastatic colorectal cancer (mCRC): Long-term survival according to prior line of treatment from CheckMate-142. Journal of Clinical Oncology. 2018;36(4_suppl):554-554. Go to original source...
    14. Overman MJ, Lonardi S, Wong KYM, et al. Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer. J Clin Oncol. 2018;36(8):773-779. doi: 10.1200/JCO.2017.76.9901. Epub 2018 Jan 20. PMID: 29355075. Go to original source... Go to PubMed...
    15. André T, et al. SO-27 Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142. Annals of Oncology. Volume 32;S213-S214. https://doi.org/10.1016/j.annonc.2021.05.051. Go to original source...
    16. Lenz HJ, Van Cutsem E, Luisa Limon M, et al. First-Line Nivolumab Plus Low-Dose Ipilimumab for Microsatellite Instability-High/Mismatch Repair-Deficient Metastatic Colorectal Cancer: The Phase II CheckMate 142 Study. J Clin Oncol. 2022;40(2):161-170. doi: 10.1200/JCO.21.01015. Epub 202;1 Oct 12. PMID: 34637336. Go to original source... Go to PubMed...
    17. Sinicrope FA, Ou FS, Zemla T, et al. Randomized trial of standard chemotherapy alone or combined with atezolizumab as adjuvant therapy for patients with stage III colon cancer and deficient mismatch repair (ATOMIC, Alliance A021502). Journal of Clinical Oncology. 2019;37(15_suppl):e15169-e15169. Go to original source...
    18. Lau D, Kalaitzaki E, Church DN, et al. Rationale and design of the POLEM trial: avelumab plus fluoropyrimidine-based chemotherapy as adjuvant treatment for stage III mismatch repair deficient or POLE exonuclease domain mutant colon cancer: a phase III randomised study. ESMO Open. 2020;5(1):e000638. doi: 10.1136/esmoopen-2019-000638. PMID: 32079623; PMCID: PMC7046393. Go to original source... Go to PubMed...
    19. Morton D. 523O-FOxTROT: An international randomised controlled trial in 1053 patients evaluating neoadjuvant chemotherapy (NAC) for colon cancer. On behalf of the FOxTROT Collaborative Group. Ann. Oncol. 2019;30(Suppl. 5):v198-v252. Go to original source...
    20. Chalabi M, Fanchi LF, Dijkstra KK, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020;26(4):566-576. doi:10.1038/s41591-020-0805-8. Epub 2020 Apr 6. PMID: 32251400. Go to original source... Go to PubMed...
    21. Liu DX, Li DD, He W, et al. PD-1 blockade in neoadjuvant setting of DNA mismatch repair-deficient/microsatellite instability-high colorectal cancer. Oncoimmunology. 2020;9(1):1711650. doi: 10.1080/2162402X.2020.1711650. PMID: 32042474; PMCID: PMC6984585. Go to original source... Go to PubMed...
    22. Ludford K, Cohen R, Svrcek M, et al. Pathological Tumor Response Following Immune Checkpoint Blockade for Deficient Mismatch Repair Advanced Colorectal Cancer. J Natl Cancer Inst. 2021;113(2):208-211. doi:10.1093/jnci/djaa052. PMID: 32294214; PMCID: PMC7850519. Go to original source... Go to PubMed...
    23. Hu H, Kang L, Zhang J, et al. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial. Lancet Gastroenterol Hepatol. 2022;7(1):38-48. doi: 10.1016/S2468-1253(21)00348-4. Epub 2021 Oct 22. PMID: 34688374. Go to original source... Go to PubMed...
    24. Lumish MA, Cohen JL, Stadler ZK, et al. PD-1 blockade alone for mismatch repair deficient (dMMR) locally advanced rectal cancer. Journal of Clinical Oncology. 2022;40(4_suppl):16-16. Go to original source...
    25. Yuki, S, Bando H, Tsukada Y, et al. Short-term results of VOLTAGE-A: Nivolumab monotherapy and subsequent radical surgery following preoperative chemoradiotherapy in patients with microsatellite stable and microsatellite instability-high locally advanced rectal cancer. J. Clin. Oncol. 2020;38:4100. Go to original source...
    26. Salvatore L, Bensi M, Corallo S, et al., Phase II study of preoperative (PREOP) chemoradiotherapy (CTRT) plus avelumab (AVE) in patients (PTS) with locally advanced rectal cancer (LARC): the AVANA study, J. Clin. Oncol. 2021;39(15_suppl): 3511, https://doi.org/10.1200/JCO.2021.39.15_SUPPL.3511. Go to original source...

    Return to the content


    Oncology

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.